Related Experiment Video

Updated: Dec 10, 2025

Non-Invasive PET/MR Imaging in an Orthotopic Mouse Model of Hepatocellular Carcinoma
07:47

Non-Invasive PET/MR Imaging in an Orthotopic Mouse Model of Hepatocellular Carcinoma

Published on: August 31, 2022

2.6K

Setanaxib as a Potent Hypoxia-specific Therapeutic Agent Against Liver Cancer

Satoshi Owada1, Hitoshi Endo2, Chisa Okada3

  • 1Department of Preventive Medicine, Tokai University School of Medicine, Isehara, Japan sowada@tsc.u-tokai.ac.jp.

Anticancer Research
|September 4, 2020
PubMed
Abstract

Insights

Setanaxib, a NOX4 inhibitor, effectively targets liver cancer cells in hypoxic conditions by inducing apoptosis and mitochondrial reactive oxygen species (ROS) accumulation. This shows promise for novel hypoxia-targeted cancer therapies.

Area of Science:

  • Oncology
  • Biochemistry
  • Cell Biology

Background:

  • Liver cancer exhibits poor prognosis, with hypoxic regions hindering drug efficacy.
  • Hypoxia-induced NADPH oxidase 4 (NOX4) and reactive oxygen species (ROS) may drive cancer malignancy.
  • The role of NOX4 in liver cancer under hypoxia requires detailed investigation.

Purpose of the Study:

  • To investigate the effects of setanaxib, a selective NOX4 inhibitor, on liver cancer cells.
  • To evaluate setanaxib's efficacy in hypoxia-induced conditions.
  • To explore the underlying mechanisms of setanaxib's action in liver cancer.

Main Methods:

  • Utilized liver cancer cell lines (HepG2, HLE, Alexander) exposed to hypoxia-mimetic cobalt chloride.
  • Performed cytotoxicity assays, immunoblot analysis, and ROS detection assays.
  • Assessed the impact of setanaxib treatment under induced hypoxic conditions.

Main Results:

  • Setanaxib demonstrated hypoxia-selective cytotoxicity, inducing apoptosis in liver cancer cells.
  • Setanaxib treatment led to mitochondrial ROS accumulation specifically under hypoxic conditions.
  • Antioxidant treatment significantly reduced setanaxib-induced cytotoxicity and apoptosis.

Conclusions:

  • Setanaxib induces apoptosis and cytotoxicity in liver cancer cells via hypoxia-selective mitochondrial ROS accumulation.
  • Setanaxib exhibits significant potential as a novel anticancer therapeutic agent for hypoxic tumors.
  • Targeting NOX4 with setanaxib offers a promising strategy for combating liver cancer in hypoxic environments.
Keywords:
Cancer treatmenthypoxialiver canceroxidative stresssetanaxib

More Related Videos

Induction and Testing of Hypoxia in Cell Culture07:01

Induction and Testing of Hypoxia in Cell Culture

Published on: August 12, 2011

86.0K
In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis12:03

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis

Published on: December 9, 2016

12.8K

Related Concept Videos

Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
6.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.5K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.7K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
352
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
315